VIP (Vasoactive Intestinal Peptide)

Quick Facts

Introduction

Vasoactive intestinal peptide (VIP) is a 28-amino-acid neuropeptide belonging to the secretin/glucagon superfamily. Originally isolated from the intestine for its blood-vessel-dilating activity — the source of its name — it is now recognized in research as a broadly distributed signaling molecule with roles spanning the nervous, immune, cardiovascular, and endocrine systems. Its standout research theme is its capacity to act as a natural anti-inflammatory and immunoregulatory agent.

Within the immunity-focused peptides catalogued in the peptide database, VIP is studied alongside molecules such as the human cathelicidin LL-37 and the anti-inflammatory tripeptide KPV. Unlike those compounds, VIP signals through dedicated G-protein-coupled receptors and is part of the body's endogenous neuro-immune communication network, making it a model molecule for the field of neuroimmunology.

This profile covers what VIP is, the receptor biology that defines it, its molecular and structural characteristics, its anti-inflammatory and vasoactive mechanisms, the immune and neuroprotective research it appears in, and how it compares with related peptides such as PACAP. It also addresses VIP's central pharmacokinetic challenge: a very short natural half-life.

What is VIP?

VIP is an endogenous neuropeptide synthesized widely throughout the body — in the central and peripheral nervous systems, the gastrointestinal tract, and immune tissues. It functions as a neurotransmitter and neuromodulator and shares strong structural homology with pituitary adenylate cyclase-activating polypeptide (PACAP), with which it shares receptors, and more distantly with secretin and glucagon.

Its biological reach is unusually broad. VIP is studied for vasodilation and smooth-muscle relaxation in the gut and airways, for regulation of secretion, for circadian rhythm signaling in the suprachiasmatic nucleus, and — most prominently in peptide research — for its ability to steer immune responses toward a tolerogenic, anti-inflammatory state. This combination of vascular, neural, and immune activity is what makes VIP a continually studied molecule.

Molecular and structural characteristics

VIP is a linear 28-residue peptide that adopts an α-helical conformation when engaging its receptors, a structural feature common to the secretin/glucagon family. The helix presents the residues that contact the receptor's extracellular domain, and the high sequence homology with PACAP explains why both peptides activate the shared VPAC receptors.

A defining structural liability is VIP's susceptibility to peptidase degradation. The native sequence is rapidly cleaved by enzymes such as dipeptidyl peptidase-4 and neutral endopeptidase, which is the basis for its short half-life and a major reason researchers have developed more stable analogues to study its biology over longer windows.

Mechanism of action

VIP exerts its effects by binding two G-protein-coupled receptors, VPAC1 and VPAC2. Receptor activation couples to Gs proteins, raising intracellular cAMP and activating protein kinase A — the canonical signaling cascade through which VIP modulates cell behavior. VPAC1 and VPAC2 differ in their tissue distribution, which helps explain VIP's diverse, context-specific actions.

In the immune system, this cAMP-driven signaling is studied for shifting responses toward an anti-inflammatory and tolerogenic profile. VIP is reported to reduce production of pro-inflammatory cytokines (such as TNF-α, IL-6, and IL-12), to promote anti-inflammatory mediators (such as IL-10), and to favor regulatory T-cell development. It also modulates antigen-presenting cells, dampening their pro-inflammatory output. These coordinated effects make VIP a model endogenous immunoregulator.

Outside immunity, the same receptor signaling underlies VIP's vasodilation and smooth-muscle relaxation, its secretory effects in the gut, and its role in circadian timekeeping in the suprachiasmatic nucleus, where VPAC2 signaling helps synchronize the central clock. In the nervous system VIP is additionally studied for neuroprotective and neurotrophic associations.

• Agonism at VPAC1 and VPAC2 G-protein-coupled receptors.
• Gs-coupled elevation of cAMP and PKA signaling.
• Suppression of pro-inflammatory cytokines; promotion of IL-10.
• Modulation of antigen-presenting cells and regulatory T cells.
• Vasodilation, smooth-muscle relaxation, and circadian signaling.

Immunomodulation and inflammation research

The most active area of VIP research is its role as an endogenous anti-inflammatory factor. In preclinical models of autoimmune and inflammatory conditions — including models of arthritis, colitis, and other immune-driven processes — VIP has been associated with reduced inflammatory damage and a shift toward immune tolerance. The proposed basis is the coordinated cytokine and cell-population changes described above, mediated through VPAC receptors.

This places VIP in the same broad research conversation as other immunity-focused peptides such as LL-37 and KPV, though VIP's mechanism is distinct: rather than acting on microbial membranes or NF-κB directly, it works through dedicated receptors and cAMP signaling to recalibrate the immune response. Its dual identity as both a neuropeptide and an immune regulator makes it a frequent reference point in neuroimmunology.

Vasoactive and neuroprotective research

VIP's original identity as a vasodilator remains an active research area. Through receptor-mediated smooth-muscle relaxation it is studied in the context of vascular tone, airway relaxation, and pulmonary circulation. Its relevance to the lungs has made VIP and its analogues a subject of interest in research on conditions involving pulmonary vascular and inflammatory pathways.

In the nervous system, VIP is studied for neuroprotective and neurotrophic associations, including support of neuronal survival and modulation of glial responses. Its role in the suprachiasmatic nucleus links it to circadian-rhythm research. Across these contexts, the recurring limitation is the peptide's rapid degradation, which is why much translational work focuses on stabilized analogues rather than native VIP.

Comparison: VIP vs PACAP vs LL-37

VIP is most closely compared with PACAP, its structural relative that shares the VPAC receptors, and is studied in the same immunity space as the antimicrobial peptide LL-37. The three illustrate different ways peptides influence immune and tissue responses.

VIP and PACAP overlap strongly because they share receptors and signaling, while LL-37 represents a mechanistically separate, membrane-active branch of immunity research. Full entries for related compounds are in the peptide database.

Half-life and pharmacokinetic considerations

VIP's defining pharmacokinetic feature is its very short half-life — on the order of minutes — owing to rapid enzymatic degradation by peptidases including dipeptidyl peptidase-4 and neutral endopeptidase. This brevity is the single biggest interpretive challenge in VIP research and the reason native VIP is difficult to study over sustained windows.

To address this, researchers have developed stabilized analogues and alternative delivery strategies designed to resist degradation or prolong receptor exposure. Findings from such analogues cannot be assumed to apply identically to native VIP, so the literature distinguishes carefully between the parent peptide and engineered variants.

Reconstitution and handling considerations

Lyophilized VIP is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken to protect the peptide. Because VIP is degradation-prone, reconstituted solution is handled promptly and kept cold; the solution should be clear, and cloudiness or particulates indicate it should be discarded.

Working concentrations are chosen so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Handle promptly and keep cold given degradation susceptibility.
• Confirm the solution is clear before use.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized VIP is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting is especially valuable for a degradation-prone peptide because it minimizes freeze–thaw cycling of any single solution.

Research limitations

VIP is a research compound whose biology, while rich, is difficult to translate. Its very short half-life limits native-peptide studies, much of the anti-inflammatory evidence comes from preclinical models, and its broad receptor distribution means effects in one system cannot be assumed to apply to another. It is described here strictly for research reference.

• Very short half-life limits the use of native VIP in vivo.
• Most anti-inflammatory data come from preclinical models.
• Broad receptor distribution produces context-dependent effects.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013.Source
2. Gomariz RP, et al. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann N Y Acad Sci. 2006.Source
3. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004.Source